Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

TheraPatch marketer hopes to "find a strategic investor, partner or an acquirer which will enable us to once again satisfy the NASDAQ SmallCap listing requirements," firm says in Nov. 27 release announcing NASDAQ stock delisting due to failure to satisfy minimum bid price and stockholder equity standards. Firm's issue now trades on OTC Bulletin Board. In 1LecTec's third quarter 10-Q filing, firm says it expects to "continue to operate at a net loss and experience negative cash flow...for the foreseeable future." While it has sufficient cash to fund operations through year end, future activities "will require additional investments...of equity or debt either by outside investors or as part of a business combination transaction." Firm reported a net loss of $370,461 in Q3, compared to a $1.2 mil. loss in the year-ago period...

You may also be interested in...


CEO Rodney Young, board member Donald Wegmiller resign from the firm in early August. LecTec co-founder and director Alan Hymes, MD, will serve as the firm's chairman and CEO until further notice. TheraPatch marketer is seeking a buyer, strategic investor or partner to boost its financials and satisfy NASDAQ listing requirements (1"The Tan Sheet" Dec. 9, 2002, In Brief)...

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts